Cullinan Wittelsbach

Cullinan Wittelsbach was a specialized biotechnology subsidiary of Cullinan Oncology (now Cullinan Therapeutics), established in 2018 to advance a novel agonistic antibody for immuno-oncology. The company was part of Cullinan's "hub-and-spoke" business model, which utilizes individual subsidiaries to house and develop specific therapeutic assets. The lead program was discovered through a collaboration with MAB Discovery GmbH using their proprietary rabbit-based antibody discovery platform. The entity was designed to provide a capital-efficient structure for the development of this specific therapeutic candidate. According to SEC filings, Cullinan Wittelsbach has since been dissolved, and its programs were either discontinued or integrated into the parent company's broader pipeline.